Stock Analysis

Eastwood Bio-Medical Canada Full Year 2024 Earnings: CA$0.007 loss per share (vs CA$0.008 loss in FY 2023)

Published
TSXV:EBM

Eastwood Bio-Medical Canada (CVE:EBM) Full Year 2024 Results

Key Financial Results

  • Revenue: CA$702.1k (down 19% from FY 2023).
  • Net loss: CA$455.9k (loss narrowed by 17% from FY 2023).
  • CA$0.007 loss per share (improved from CA$0.008 loss in FY 2023).
TSXV:EBM Earnings and Revenue History March 5th 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

Eastwood Bio-Medical Canada shares are up 30% from a week ago.

Risk Analysis

You should always think about risks. Case in point, we've spotted 4 warning signs for Eastwood Bio-Medical Canada you should be aware of, and 3 of them are significant.

Valuation is complex, but we're here to simplify it.

Discover if Eastwood Bio-Medical Canada might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.